Law Offices of Thomas J. Lamb

  • About Our Firm
  • Drug Injury
  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Breast Implants
  • Free Case Evaluation
  • FAQs

Ocaliva Drug Label Warnings vis-à-vis FDA Ocaliva Safety Signal Investigation

October 19, 2020 By Law Offices of Thomas J. Lamb, P.A.

In our last article, we reported on the current FDA investigation of an Ocaliva safety signal which, although it began in May 2020, only became public knowledge in October. The best we can tell, it is a possible Ocaliva liver toxicity issue that is the subject of this Ocaliva FDA investigation. Now we have some additional information about some … [Read more...]

Filed Under: Unsafe Drugs Tagged With: liver damage, liver failure, liver injury, Ocaliva

A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

October 16, 2020 By Law Offices of Thomas J. Lamb, P.A.

Background:  Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterized by limited treatment options and a poor prognosis. At relapse after platinum-based chemotherapy, single-agent chemotherapy is commonly used and single-arm trials of immune-checkpoint inhibitors have demonstrated encouraging activity. Patients and … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Current Ocaliva Liver Safety FDA Evaluation Started Back in May 2020

October 15, 2020 By Law Offices of Thomas J. Lamb, P.A.

In October 2020 we first learned about a "new" drug safety issue for Ocaliva -- although it apparently has been on the FDA's radar since at least May 2020. It seems a possible Ocaliva liver-related side effects risk has attracted scrutiny, and there is an Ocaliva liver safety FDA evaluation underway. It was this October 9, 2020, Endpoints News … [Read more...]

Filed Under: Unsafe Drugs Tagged With: drug-induced liver injury, liver damage, liver failure, liver injury, Ocaliva

FDA Approves Drug Combination for Treating Mesothelioma

October 12, 2020 By Law Offices of Thomas J. Lamb, P.A.

[On October 02, 2020], the U.S. Food and Drug Administration approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery. This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic … [Read more...]

Filed Under: Uncategorized

Beovu-associated Endophthalmitis is “New” for Beovu Eye Drug Safety Issue of Vision Loss

October 8, 2020 By Law Offices of Thomas J. Lamb, P.A.

In this article, we will look at the Beovu-associated endophthalmitis and Beovu-associated retinal detachment aspects of the Beovu eye drug safety issue of vision loss. New warnings for these vision-related side effects were added in June 2020 when Novartis revised the Prescribing Information for Beovu. In the Beovu drug label, or “Full … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Beovu, blindness, endophthalmitis, intraocular inflammation, occlusive vasculitis, retinal detachment, vision loss

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

October 2, 2020 By Law Offices of Thomas J. Lamb, P.A.

Background:  There is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in this disease. We aimed to evaluate the activity of durvalumab, an anti-PD-L1 antibody, given during … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Beovu Use Continues Despite Ongoing Beovu-associated Inflammation Investigation

October 2, 2020 By Law Offices of Thomas J. Lamb, P.A.

A summary of the Beovu-associated inflammation safety issue is presented in this July 2020 Journal of VitreoRetinal Diseases Research Article, “Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab”. From the Abstract for this item we get these details about the current Beovu safety issue under investigation: Conclusions: … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Beovu, blindness, intraocular inflammation, occlusive retinal vasculitis, retinal artery occlusion, vision loss

Safety of Beovu Update: Study Results Announcement by Novartis and Beovu Label Change in Europe

September 24, 2020 By Law Offices of Thomas J. Lamb, P.A.

A September 2020 announcement by Novartis about recent Beovu study results had an emphasis on the safety of Beovu. However, this is understandable in view of a February 2020 notification issued by the American Society of Retina Specialists (ASRS) which raised questions about the safety of Beovu. We get the following from this September 14, … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Beovu, blindness, intraocular inflammation, retinal vascular occlusion, retinal vasculitis, vision loss

FDA clears IND application for CAR T-cell therapy for advanced mesothelioma

September 22, 2020 By Law Offices of Thomas J. Lamb, P.A.

The FDA cleared an investigational new drug application for ATA2271, a chimeric antigen receptor T-cell therapy [ or CAR T-cell therapy ] for the treatment of advanced mesothelioma, according to the agent’s manufacturer. ATA2271 (Atara Biotherapeutics) is an autologous CAR T-cell therapy that targets the mesothelin antigen expressed on the … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments

FDA Belviq Recall Decision Came After Safety Data Review Found Excess Cancers Risks

September 22, 2020 By Law Offices of Thomas J. Lamb, P.A.

In this FDA staff article, “Cancer risk associated with lorcaserin — The FDA’s review of the CAMELLIA-TIMI 61 trial”, which was published by the New England Journal of Medicine (NEJM), the early 2020 FDA Belviq recall decision was explained. Essentially, this FDA action after a careful analysis of Belviq safety data that revealed excess … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Belviq, Colon cancer, leukemia, lung cancer, Pancreatic Cancer, Rectal cancer

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 50
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • Drug Injury Cases
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • GenX Cancer Cases
  • Breast Implant Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • About Our Firm
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2021 · Law Offices of Thomas J. Lamb, P.A.